Aprea Therapeutics (APRE) Proxy Filing summary

Voting matters and shareholder proposals

• Election of three Class III directors: Jean-Pierre Bizzari, Oren Gilad, and John B. Henneman III, with board recommendation to vote for all nominees.

• Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2025, recommended for approval.

• Advisory vote to approve executive compensation, with board recommending approval.

• Advisory vote on the frequency of future executive compensation votes, with a recommendation for annual votes.

Board of directors and corporate governance

• Board composition includes at least three Class III directors up for election at the 2025 annual meeting.

Executive compensation and say-on-pay

• Shareholders are asked to approve, on a non-binding basis, the compensation of named executive officers.

• Advisory vote on the frequency of future say-on-pay votes is included, with a recommendation for annual votes.